secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2024-02-09T23:59:59+00:00
Accession:  0001493152-24-005649
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AIM ImmunoTech reports positive Phase 2 topline results for Ampligen in post-COVID fatigue
--------------------------------------------------------------------------------

- Primary endpoint (PROMIS Fatigue Score at week 13) not significant; Ampligen showed lower fatigue at multiple timepoints vs placebo.
- Secondary and ad hoc analyses showed differences in PROMIS Fatigue Score reaching or approaching statistical significance at several timepoints.
- Six-Minute Walk Test: Ampligen group had higher distance traveled at week 13 vs placebo.
- Safety: Ampligen generally well tolerated; no severe TEAEs or deaths. 15% mild treatment-related TEAEs in Ampligen group.
- Study enrolled 80 subjects (40 per arm); 82.5% completed (90% Ampligen, 75% placebo).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315224005649/0001493152-24-005649-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315224005649/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-005649

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer